Join Growin Stock Community!

Immunome, inc.IMNM.US Overview

US StockHealthcare
(No presentation for IMNM)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IMNM AI Insights

IMNM Overall Performance

IMNM AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IMNM Recent Performance

0.71%

Immunome, inc.

0.05%

Avg of Sector

-0.31%

S&P500

IMNM PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IMNM Key Information

IMNM Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IMNM Profile

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Price of IMNM

IMNM FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IMNM Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.43
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
249.19
PB Ratio
9.13
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-2301.30%
Revenue Growth (YoY)
-4.44%
Profit Growth (YoY)
-4.44%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.43
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
249.19
PB Ratio
9.13
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-2301.30%
Revenue Growth (YoY)
-4.44%
Profit Growth (YoY)
-4.44%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is IMNM's latest earnings report released?

    The most recent financial report for Immunome, inc. (IMNM) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IMNM's short-term business performance and financial health. For the latest updates on IMNM's earnings releases, visit this page regularly.

  • How is IMNM's revenue growth?

    In the latest financial report, Immunome, inc. (IMNM) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does IMNM have?

    At the end of the period, Immunome, inc. (IMNM) held Total Cash and Cash Equivalents of 272.85M, accounting for 0.91 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is IMNM's EPS continuing to grow?

    According to the past four quarterly reports, Immunome, inc. (IMNM)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.65. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IMNM?

    Immunome, inc. (IMNM)'s Free Cash Flow (FCF) for the period is -41.63M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 16.58% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.